VTGN MEXC RealStocks
Own real VTGN shares through MEXC's regulated brokerage partner.
Suitable for long-term holding.
- Own the actual shares
- Receive dividends and voting rights
- Buy fractional shares starting at $1
Last updated: 2026-11-13 23:30:40. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Vistagen Therapeutics, Inc. (VTGN) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $0.18, with a market capitalization of $7.93M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.16 to $5.14. This page covers its latest market performance, valuation, price trends and company information.
$7.93M | |
$0.18 | |
$0.19 | |
$0.18 | |
$0.18 | |
395.96K | |
10.45M | |
-- | |
$5.14 | |
$0.16 | |
-- | |
-- |
Vistagen Therapeutics, Inc. (VTGN) is trading at $0.18 in after-hours trading as of 2026-11-13 22:40:00, down 1.10% ($0.00) from the regular-session close of $0.18.
After-hours trading shows how investors are pricing VTGN after the regular session closes. The current after-hours price is below the regular-session close, indicating cautious after-hours sentiment.
Over the past seven days, Vistagen Therapeutics, Inc. (VTGN) moved from $0.17 to $0.18, representing a gain of 9.56% ($0.02).
The stock traded between $0.16 and $0.19 during the period. The latest price is near the middle of the 7-day range, indicating strong upward.
The average daily volume was 611.81 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 0.3%
VTGN is currently trading at $0.18, placing it 0.3% of the way from its 52-week low of $0.16 to its 52-week high of $5.14. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Vistagen Therapeutics Inc is a late clinical-stage therapeutics company focused on developing and commercializing medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue, and cancer cachexia. The company is engaged in developing intranasal product candidates called pherines, which leverage the understanding of nose-to-brain neurocircuitry. Vistagen's pherine pipeline consists of various product candidates like: Fasedienol, Itruvone, PH15, Refisolone, and PH284, which are being developed to provide treatment for a variety of disorders. Additionally, it is seeking potential partners for the further clinical development and commercialization of an oral drug candidate, AV-101, to treat certain neurological disorders.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 41 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Vistagen Therapeutics, Inc. (VTGN) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to VTGN, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between VTGN shares and USD.
VTGN Shares to USD
1.00 VTGN shares = 0.181 USD
Calculations are estimates based on the latest available price and are for reference only.